|1.||Hoglen, Niel C: 2 articles (03/2007 - 05/2004)|
|2.||Rabasseda, X: 2 articles (07/2004 - 06/2004)|
|3.||Bayes, M: 2 articles (07/2004 - 06/2004)|
|4.||Prous, J R: 2 articles (07/2004 - 06/2004)|
|5.||Gores, Gregory J: 2 articles (03/2004 - 03/2003)|
|6.||Spada, A: 1 article (07/2015)|
|7.||Elbekai, R H: 1 article (07/2015)|
|8.||Paranjpe, M G: 1 article (07/2015)|
|9.||Contreras, P C: 1 article (07/2015)|
|10.||Pockros, P: 1 article (05/2010)|
03/01/2007 - "This study examined the efficacy of the caspase inhibitor, IDN-6556, in a rat model of liver ischemia-reperfusion injury. "
03/01/2003 - "When added to the preservation solution, the caspase inhibitor IDN-6556 appears to be a feasible therapeutic agent against ischemia-reperfusion injury in liver transplantation."
03/01/2007 - "IDN-6556 present in cold storage media ameliorated liver injury due to cold ischemia and reperfusion injury and may be a rational therapeutic approach to reduce the risk of liver ischemia in the clinical setting."
|2.||Liver Diseases (Liver Disease)
08/01/2007 - "The purpose of this study was to further explore the effect of IDN-6556 in patients with liver disease in a multicenter, double-blind, placebo-controlled, dose-ranging study with a 14-day dosing period. "
05/01/2004 - "The potency, efficacy, and pharmacokinetic properties of IDN-6556 (3-[2-[(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid), a first-in-class caspase inhibitor in clinical trials for the treatment of liver diseases, were characterized in vivo in rodent models. "
10/01/2007 - "Prolonged retention of PF-03491390 in the liver after oral administration has the benefit of low systemic exposure, making this a beneficial agent for the treatment of liver diseases."
05/01/2004 - "This evaluation indicates that IDN-6556 has marked efficacy in models of liver disease after oral administration and thus, is an excellent candidate for the treatment of liver diseases characterized by excessive apoptosis."
05/01/2010 - "PF-03491390 inhibits multiple caspases and lowers serum AST and ALT levels in patients with chronic liver diseases. "
|3.||Chronic Hepatitis C
05/01/2010 - "Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C."
08/01/2007 - "Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C."
03/01/2004 - "To ascertain the net effect of inhibiting liver cell apoptosis on liver injury, inflammation, and hepatic fibrogenesis, we examined the effect of a pancaspase inhibition IDN-6556 on these parameters in the bile duct ligated (BDL) mouse. "
08/01/2007 - "Longer studies to assess potential effects of IDN-6556 on liver inflammation and fibrosis are merited."
|1.||Brain Natriuretic Peptide (Natrecor)
|4.||Sodium Oxybate (gamma Hydroxybutyrate)
|6.||Niacin (Nicotinic Acid)
|8.||Aminolevulinic Acid (Levulan)
|10.||((1- ((2- amino- 9H- purin- 9- yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxyl